These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23923255)

  • 1. Effect of zoledronic acid on bone density and markers of bone turnover in a community clinic.
    Lim R; Zailskas S; Goldsby TU; Lukens C; Muravev R; Dulipsingh L
    Conn Med; 2013; 77(6):357-9. PubMed ID: 23923255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
    Brown JE; Ellis SP; Lester JE; Gutcher S; Khanna T; Purohit OP; McCloskey E; Coleman RE
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5406-10. PubMed ID: 17875770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
    J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
    Bubbear JS; Gall A; Middleton FR; Ferguson-Pell M; Swaminathan R; Keen RW
    Osteoporos Int; 2011 Jan; 22(1):271-9. PubMed ID: 20358358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.
    Greenspan SL; Perera S; Ferchak MA; Nace DA; Resnick NM
    JAMA Intern Med; 2015 Jun; 175(6):913-21. PubMed ID: 25867538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
    Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
    Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid in osteoporosis secondary to mastocytosis.
    Rossini M; Zanotti R; Viapiana O; Tripi G; Idolazzi L; Biondan M; Orsolini G; Bonadonna P; Adami S; Gatti D
    Am J Med; 2014 Nov; 127(11):1127.e1-1127.e4. PubMed ID: 24954632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women.
    Hossain M; Chowdhury IH; Emran MA; Habib AH; Asaduzzamnan AK; Alam M; Ferdous C
    Bangladesh Med Res Counc Bull; 2010 Dec; 36(3):74-7. PubMed ID: 21548542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.